Hepatic encephalopathy

2 papers1 finding

Humans1
Animals1

Associations

1

Empagliflozin

downin humans1

1 study

Empagliflozin lowers the risk of hepatic encephalopathy in humans (4.0% vs. 4.7%).
Humansversus dapagliflozin in matched adults with liver cirrhosis
Empagliflozin versus dapagliflozin in patients with liver cirrhosis: A comparative real-world study on hepatic decompensation
Hepatology forum14 Apr 2026

More on Empagliflozin

Trial sponsors

Asian Institute Of Medical Sciences
1 trialPhase 4220 people
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
1 trialPhase 430 people
Tampa General Hospital
1 trialPhase 44 people
University of Pittsburgh
1 trialPhase 3184 people
Tanta University
1 trialPhase 2/3150 people
Sherief Abd-Elsalam
1 trialPhase 2/3120 people
Air Force Military Medical University, China
2 trialsPhase 1/266 people

Latest

3 in 12 months

Research Square12 Aug

Pharmacological Downregulation of Fetuin-A Attenuates TLR4-mediated Neuroinflammation in Aged Rats with Minimal Hepatic Encephalopathy

Preprint: experiments in ratsInterventions

Cureus11 Aug

Effect of an Integrated Exercise Training Program on Muscle Mass and Functional Capacity in Sarcopenic Patients With Decompensated Liver Cirrhosis

Randomised trial in 40 peopleExercise

Hepatology Forum7 Aug

Empagliflozin versus dapagliflozin in patients with liver cirrhosis: A comparative real-world study on hepatic decompensation

Cohort study in peopleEmpagliflozin